In this 4th edition of B2B GU Cancers Triad, SIU will convene world-renowned experts for a state-of-the-art meeting focused on the latest research in the top three GU cancers: bladder, kidney, and prostate. View the programme agenda here.

Event Description

The treatment of GU malignancies has seen tremendous revolution in recent years. BCa, RCC, and PCa are the most frequently encountered GU malignancies and represent a heterogeneous population of cancers, in both histology and approach to treatment. These three cancers continue to undergo major paradigm shifts in their respective therapeutic landscapes as we expand our understanding of their underlying molecular and oncogenic mechanisms.

Building on the success of the first three editions of the GU Cancers Triad Meeting in 2019, 2020, and 2021, the SIU will convene a follow-up hybrid meeting (in-person and virtually) during the 42nd Congress of the SIU. For one full day, world-renowned experts will focus on the latest research in the top three GU cancers: bladder, kidney, and prostate.

The increasingly complex treatment landscape for bladder, kidney, and prostate cancers poses a challenge for urologists, medical oncologists, and radiation oncologists alike. In managing these GU cancers, physicians need to keep up with new data on all treatment options, select therapies on an individual case basis, and use the optimal sequence or combinations while effectively managing side effects.

The topics will enhance the target audience’s understanding of the latest trends in diagnostic modalities and treatment approaches. It will include a discussion of the challenges and opportunities that new therapeutic approaches in these fields offer. In addition, this programme includes interactive debates and panel discussions to facilitate understanding of how advances in diagnosis and treatment can best be integrated into patient care.

Meet this year's expert faculty!

Learning Objectives

At the end of this programme, participants will be able to:

• Evaluate the benefits and risks of various treatment options across the treatment continuum in UC, RCC, and PCa.
• Analyze novel agents and treatment approaches for the evolving management of GU cancers based on emerging clinical data.
• Discuss strategies to identify and manage adverse events related to systemic treatment, including immunotherapy.
• Evaluate the role of imaging or genetic markers in guiding treatment decision-making.
• Discuss the importance of personalized medicine, based on costs and patient preference, while minimizing toxicity and maximizing efficacy.

This meeting will be transmitted live on SIU@U and webcasts will also be available on-demand. Keep the conversation going by sharing your thoughts and questions with colleagues on social media using #B2BGUCancerTriad